Skip to main content
. Author manuscript; available in PMC: 2022 May 26.
Published in final edited form as: Mol Cancer Res. 2021 Jan 29;19(5):913–920. doi: 10.1158/1541-7786.MCR-20-0738

Figure 4: Effect of gilteritinib on apoptotic-related proteins.

Figure 4:

SUP-M2 and SU-DHL-1 cells were treated with the indicated concentrations of gilteritinib for 24 hours. At the end of the treatment, cell lysates were prepared, and Western blot analyses were performed for cleaved PARP, caspases 3, 9, BAD, Survivin, MCL1, and c-Myc. β-Actin served as the loading control.